Get the Stockscreener App
6.32
2.10%
0.13
Cytek Biosciences Inc Stock (CTKB) Forecast
The Cytek Biosciences Inc (CTKB) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $0.7113, representing a -88.75% decrease from the current price of $6.32. The highest analyst price target is $1.3749, and the lowest is $0.0477.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month CTKB Price Target
Average 3.255
(-48.50% Downside)
Is Cytek Biosciences Inc (CTKB) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 49.18 | Neutral |
| STOCH(9,6) | 29.87 | Neutral |
| STOCHRSI(14) | 21.41 | Neutral |
| MACD(12,26) | 0.0441 | Sell |
| ADX(14) | 14.30 | Neutral |
| William %R | -67.44 | Neutral |
| CCI(14) | -92.63 | Neutral |
Buy: 0
Sell: 1
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
6.453
Sell
|
6.3956
Sell
|
| MA20 |
6.5268
Sell
|
6.4086
Sell
|
| MA50 |
6.0298
Buy
|
6.159
Buy
|
| MA100 |
5.6926
Buy
|
5.9874
Buy
|
| MA200 |
5.9233
Buy
|
6.1021
Buy
|
Buy: 6
Sell: 4
Neutral: 0
Summary: Buy
According to our latest analysis, CTKB could be considered a Neutral, with 17 technical analysis indicators signaling 6 Buy signals, 5 signaling Sell signals and 6 Neutral signals. This suggests that investors should exercise caution when entering new positions on CTKB, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 49.18 indicates that CTKB is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 29.87 indicates that CTKB is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 21.41 indicates that CTKB is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 14.3 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -92.63 indicates that CTKB is still oversold but not to an extreme extent.
Long-term CTKB price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Cytek Biosciences Inc financial reports and earnings history, Cytek Biosciences Inc (CTKB) stock could reach $19.47 by 2030, $38.43 by 2040 and $103.61 by 2050. See the projected annual prices until 2050 of the Cytek Biosciences Inc stock below:
- Cytek Biosciences Inc (CTKB) is expected to reach an average price of $16.37 in 2035, with a high prediction of $19.76 and a low estimate of $17.53. This indicates an $158.97% rise from the last recorded price of $6.32.
- Cytek Biosciences Inc (CTKB) stock is projected to chart a bullish course in 2040, with an average price target of $35.23, representing an $457.45% surge from its current level. The forecast ranges from a conservative $37.28 to a sky-high $38.43.
- Our analysts predict Cytek Biosciences Inc (CTKB) to jump 892.42% by 2045, soaring from $63.18 to an average price of $62.72, potentially reaching $64.87. While $63.18 is the low estimate, the potential upside is significant.
- Cytek Biosciences Inc (CTKB) stock is expected to climb by 2050, reaching an average of $103.44, a $1,537% jump from its current level. However, a wide range of estimates exists, with high and low targets of $103.61 and $103.73, respectively, highlighting the market's uncertainty.
Cytek Biosciences Inc Stock (CTKB) Year by Year Forecast
Cytek Biosciences Inc Stock (CTKB) Price Forecast for 2025
Cytek Biosciences Inc Stock (CTKB) is expected to reach an average price of $3.255 in 2025, with a high prediction of $6.4623 and a low estimate of $0.0477. This indicates an -48.50% fall from the last recorded price of $6.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $0.7449 | $0.0477 | $1.3749 | -88.21% |
| February, 2025 | $4.7838 | $0.5921 | $4.8238 | -24.31% |
| March, 2025 | $1.6328 | $1.2228 | $5.8611 | -74.17% |
| April, 2025 | $4.9889 | $1.30 | $5.5189 | -21.06% |
| May, 2025 | $6.0679 | $3.8234 | $6.2879 | -3.99% |
| June, 2025 | $5.4768 | $4.3296 | $6.4623 | -13.34% |
| July, 2025 | $1.503 | $1.423 | $5.634 | -76.22% |
| August, 2025 | $2.2319 | $0.7174 | $2.5319 | -64.69% |
| September, 2025 | $4.8608 | $2.0391 | $4.9808 | -23.09% |
| October, 2025 | $2.367 | $0.937 | $5.2981 | -62.55% |
| November, 2025 | $1.1759 | $0.0987 | $2.4792 | -81.39% |
| December, 2025 | $4.1921 | $0.5132 | $4.5821 | -33.67% |
Cytek Biosciences Inc Stock (CTKB) Price Forecast for 2026
The predicted value for Cytek Biosciences Inc (CTKB) in 2026 is set at an average of $2.2643. Estimates vary from a peak of $4.5193 to a trough of $0.00917, indicating an -64.17% surge from the present price of $6.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $0.311 | $0.216 | $4.2093 | -95.08% |
| February, 2026 | $0.76 | $0.2783 | $1.5428 | -87.97% |
| March, 2026 | $1.8589 | $0.5172 | $2.4817 | -70.59% |
| April, 2026 | $1.7051 | $1.5751 | $2.6151 | -73.02% |
| May, 2026 | $0.344 | $0.204 | $1.6723 | -94.56% |
| June, 2026 | $0.937 | $0.2065 | $1.0313 | -85.17% |
| July, 2026 | $1.6209 | $1.4148 | $1.5581 | -74.35% |
| August, 2026 | $1.1581 | $0.00917 | $1.4431 | -81.68% |
| September, 2026 | $3.6242 | $1.0753 | $4.3742 | -42.65% |
| October, 2026 | $3.2132 | $2.2559 | $3.7528 | -49.16% |
| November, 2026 | $3.4721 | $2.2176 | $3.8021 | -45.06% |
| December, 2026 | $2.1983 | $1.8283 | $4.5193 | -65.22% |
Cytek Biosciences Inc Stock (CTKB) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Cytek Biosciences Inc (CTKB) is $6.8833, with a high forecast of $12.68 and a low forecast of $1.0817. This indicates an +8.91% increase from the last price of $6.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $1.6472 | $1.5227 | $2.4972 | -73.94% |
| February, 2027 | $1.6689 | $1.0817 | $2.2561 | -73.59% |
| March, 2027 | $7.1921 | $6.2855 | $5.5971 | +13.80% |
| April, 2027 | $10.64 | $8.4527 | $8.6502 | +68.42% |
| May, 2027 | $9.7464 | $10.41 | $9.4509 | +54.21% |
| June, 2027 | $9.894 | $9.8119 | $9.764 | +56.55% |
| July, 2027 | $12.12 | $11.14 | $11.41 | +91.71% |
| August, 2027 | $13.01 | $12.25 | $11.81 | +105.83% |
| September, 2027 | $11.77 | $12.78 | $12.68 | +86.17% |
| October, 2027 | $11.48 | $11.56 | $11.62 | +81.62% |
| November, 2027 | $9.7302 | $10.32 | $10.11 | +53.96% |
| December, 2027 | $5.4779 | $5.8479 | $8.6258 | -13.32% |
Cytek Biosciences Inc Stock (CTKB) Price Forecast for 2028
In 2028, Cytek Biosciences Inc (CTKB) is projected to reach an average price of $5.7849, with a high projection of $8.02 and a low estimate of $3.5498. This indicates an -8.47% fall from the last price of $6.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $8.15 | $6.8584 | $8.02 | +28.96% |
| February, 2028 | $4.7421 | $6.4711 | $6.1366 | -24.97% |
| March, 2028 | $3.3698 | $3.5498 | $4.1532 | -46.68% |
| April, 2028 | $4.1319 | $4.2799 | $3.5819 | -34.62% |
| May, 2028 | $7.7396 | $5.7223 | $7.2096 | +22.46% |
| June, 2028 | $6.3917 | $6.6617 | $7.2751 | +1.13% |
| July, 2028 | $4.2139 | $4.4839 | $5.2223 | -33.33% |
| August, 2028 | $7.2615 | $5.9194 | $5.7065 | +14.90% |
| September, 2028 | $6.9336 | $7.307 | $6.6381 | +9.71% |
| October, 2028 | $3.5358 | $4.2258 | $5.2892 | -44.05% |
| November, 2028 | $6.8134 | $7.1634 | $7.7018 | +7.81% |
| December, 2028 | $5.8856 | $6.4445 | $6.369 | -6.87% |
Cytek Biosciences Inc Stock (CTKB) Price Forecast for 2029
The 2029 price forecast for Cytek Biosciences Inc Stock (CTKB) is $9.6028 on average, with a high prediction of $17.38 and a low estimate of $1.8256. This represents an +51.94% increase from the previous price of $6.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $4.8932 | $4.9032 | $5.7111 | -22.58% |
| February, 2029 | $5.7454 | $4.9243 | $5.0254 | -9.09% |
| March, 2029 | $5.9375 | $5.4964 | $5.4729 | -6.05% |
| April, 2029 | $7.4596 | $6.618 | $6.9941 | +18.03% |
| May, 2029 | $7.0073 | $7.7251 | $7.6262 | +10.87% |
| June, 2029 | $4.2794 | $4.6494 | $5.7528 | -32.29% |
| July, 2029 | $1.8715 | $1.9915 | $3.5249 | -70.39% |
| August, 2029 | $2.8692 | $2.3737 | $1.9581 | -54.60% |
| September, 2029 | $1.2413 | $1.8256 | $2.3547 | -80.36% |
| October, 2029 | $2.919 | $2.0874 | $2.399 | -53.81% |
| November, 2029 | $3.0111 | $2.799 | $2.6611 | -52.36% |
| December, 2029 | $18.93 | $2.7077 | $17.38 | +199.53% |
Cytek Biosciences Inc Stock (CTKB) Price Forecast for 2030
Cytek Biosciences Inc Stock (CTKB) is expected to reach an average price of $19.27 in 2030, with a high forecast of $23.73 and a low forecast of $14.81. This signifies an +204.94% surge from the last price of $6.32.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $19.83 | $18.88 | $19.47 | +213.79% |
| February, 2030 | $22.18 | $21.01 | $21.43 | +251.02% |
| March, 2030 | $20.81 | $21.72 | $21.47 | +229.24% |
| April, 2030 | $21.57 | $21.92 | $21.47 | +241.31% |
| May, 2030 | $23.29 | $22.76 | $23.19 | +268.55% |
| June, 2030 | $24.04 | $23.82 | $23.51 | +280.31% |
| July, 2030 | $22.92 | $23.22 | $23.73 | +262.61% |
| August, 2030 | $20.83 | $22.32 | $22.04 | +229.60% |
| September, 2030 | $19.22 | $20.24 | $20.53 | +204.17% |
| October, 2030 | $16.71 | $16.04 | $18.58 | +164.32% |
| November, 2030 | $15.61 | $17.34 | $17.98 | +146.97% |
| December, 2030 | $14.35 | $14.81 | $15.92 | +127.08% |
1.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):